Summary:
An MRI is recommended for an ovarian mass that is indeterminate on ultrasound. The ROMA score (combining CA125 and HE4) can also be calculated (Grade A). In presumed early-stage ovarian or tubal cancers, the following procedures should be performed: an omentectomy (at a minimum, infracolic), an appendectomy, multiple peritoneal biopsies, peritoneal cytology (grade C), and pelvic and para-aortic lymphadenectomies (Grade B) for all histologic types, except the expansile mucinous subtypes, for which lymphadenectomies can be omitted (grade C). Minimally invasive surgery is recommended for early-stage ovarian cancer, when there is no risk of tumor rupture (grade B). Adjuvant chemotherapy by carboplatin and paclitaxel is recommended for all high-grade ovarian and tubal cancers (FIGO stages I-IIA) (grade A). For FIGO stage III or IV ovarian, tubal, and primary peritoneal cancers, a contrast-enhanced computed tomography (CT) scan of the thorax/abdomen/pelvis is recommended (Grade B), as well as laparoscopic exploration to take multiple biopsies (grade A) and a carcinomatosis score (Fagotti score at a minimum) (grade C) to assess the possibility of complete surgery A C C E P T E D M A N U S C R I P T
Introduction
Initial management of epithelial ovarian cancers is relatively heterogeneous in France, with treatment sequences that differ substantially between centers for primary or interval surgery.
Similarly, the extent of surgery and the surgical staging procedures vary according to patient characteristics (young vs elderly women, for example). Perioperative management, whether it concerns early recovery or fertility preservation, has not been standardized, although it can cause physical or psychological morbidity. Finally, cancer centers vary widely in their use of chemotherapy (and how they administer it), as well as of targeted therapies; a national strategy remains to be defined, according to different clinical contexts. Work to develop
clinical practice guidelines is therefore necessary to enable practices to be homogenized in accordance with the best evidence and to improve prognosis for all patients. Accordingly, the French research group for oncologic gynecologic surgery (FRANCOGYN), the French national college of gynecologists and obstetricians (CNGOF), the French society of gynecologic oncology (SFOG), and the national investigators' group for studies in ovarian and breast cancer (GINECO-ARCAGY) jointly brought together a working group to develop such guidelines. This text is a synthesis of clinical practice guidelines for the initial management of epithelial ovarian, tubal, or primary peritoneal cancers (excluding recurrence of ovarian cancer and borderline tumors). 1 The development of these clinical practice guidelines followed the standards set by the French national authority for health (HAS) and the national cancer institute (INCa), with reviews by experts both within and outside the working group. [1] [2] [3] INCa has endorsed these clinical practice guidelines.
Their aim is to aid professionals (gynecologic surgeons, surgeons specialized in gynecologic oncology, medical gynecologists, gynecologist-obstetricians, pathologists, medical oncologists, radiologists, anesthetist-critical-care specialists, nuclear physicians, general practitioners, midwives, and paramedical personnel) in managing women with ovarian cancer or with suspected ovarian, tubal, or primary peritoneal cancer. (Table 1) :
I-
-The mass is classified as malignant if at least one M (malignant) rule applies and no B (benign) rule applies.
-The mass is classified as benign if at least one B rule applies and no M rule applies.
-It cannot be classified (or is indeterminate) if at least one M rule and one B rule both apply or if no rule applies.
Software is available without charge at the IOTA site (www.iotagroup.org), and an application is available for both Android and iOS. Around 25% of adnexal masses remain indeterminate with the Simple Rules and require a second-line examination.
When an adnexal mass is complex or indeterminate on ultrasound, a pelvic MRI is recommended (grade A). MRI to characterize an adnexal mass should use T2, T1, T1
Fat Sat, dynamic contrast-enhanced, diffusion-weighted, and gadolinium-enhanced sequences (grade B) to improve diagnostic sensitivity (grade B). It is recommended that an MRI report characterizing an adnexal mass include a malignancy risk score (such as ADNEX MR, Table 2 The ROMA score (based on serum assays of HE4 and CA125) can be used for an adnexal mass that is indeterminate on ultrasound (grade A). 4 The CNAM-TS (French national health insurance fund) does not reimburse the HE4 serum assay.
When an adnexal mass is suspected to be an ovarian cancer, an intraoperative pathology examination can be performed to enable optimal surgical staging during a single surgical procedure and thus avoid the need for reintervention (grade B). 3 In presumed early-stage ovarian cancer, the following procedures have to be performed:
an omentectomy (at a minimum, infracolic), an appendectomy, peritoneal biopsies, Laparoscopy is recommended to assess the feasibility of surgical resection that leaves no macroscopic tumor residue (i.e., complete surgery) in a woman with ovarian, tubal, or primary peritoneal carcinomatosis before laparotomic surgery (grade A). 4 Several scores for assessing the extension of peritoneal carcinomatosis have been developed. The Fagotti score is a laparoscopic score based on 7 indicators rated 0 or 2 ( Table   3 ). CT nor palpable at primary surgery after complete resection) to either systematic dissection or no dissection. This study found an identical overall survival rate among women who did and did not have dissections among the selected population, i.e., women with neither radiologic nor clinical adenopathy (LE2). On the other hand, benefits for both overall and recurrencefree survival were observed for systematic dissections when clinically or radiologically suspicious lymph nodes were present (LE2).
In advanced ovarian, tubal, or primary peritoneal cancer with no macroscopic tumor residue at the end of surgery, para-aortic and pelvic lymphadenectomies are Elderly with no frailty with ovarian, tubal, or primary peritoneal cancers should receive intravenous chemotherapy identical to that for younger women (i.e., two agents,
platinum-based) (grade B)
.
Neoadjuvant chemotherapy was most cost-effective in elderly women at high risk of complications (i.e., age ≥ 75 years and FIGO stage IV or age ≥ 75 years and stage III and at least 1 comorbidity) in the SEER database (LE4); in the EORTC study, it was associated with a lower complication rate and a higher rate of optimal surgery for elderly women (LE4).
In advanced ovarian, tubal, and primary peritoneal cancers, neoadjuvant chemotherapy diminishes the complexity of the surgical procedure and the perioperative morbidity and mortality of the interval surgery (LE1). In these advanced stage cancers, starting with chemotherapy is a good alternative for those 70 years or older with comorbidities or with extensive peritoneal carcinomatosis requiring complex initial surgery (LE4).
IVPerioperative prehabilitation for and recovery from ovarian cancer surgery 12
Preoperative management Similarly no specific data about these cancers justify guidelines for preoperative bowel preparation. No data justify a recommendation about intravenous administration of lidocaine or ketamine during surgery or the perioperative prescription of gabapentine or pregabalin.
Intraoperative management

Postoperative management
Early oral feeding is recommended, including after gastrointestinal resection for ovarian, tubal, or primary peritoneal cancer (Grade B).
The establishment of protocols for enhanced recovery after surgery (ERAS), including early mobilization, is recommended to reduce the length of stay after surgery for these cancers (Grade C). In all cases, the prescription of HRT and its dosage and administration must follow the same guidelines as those for the general population (see, HAS guidelines 2014).
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